NanoSyrinx, a Coventry, UK-based synthetic biology company, raised approx. £10M in funding.
The round was led by BGF, Octopus Ventures and M Ventures, with participation from new corporate investor, Eli Lilly and Company, and existing investors, IQ Capital and Meltwind.
The company intends to use the funds to accelerate the growth of its platform and the development of biologic therapeutics against a pipeline of previously ‘undruggable’ intracellular targets.
Led by CEO Dr. Joe Healey, NanoSyrinx is a synthetic biology company developing nanosyringes as a novel platform technology for the targeted intracellular delivery of biological molecules. The platform is based around naturally occurring ‘nanosyringes’ which are engineered to selectively deliver peptide and protein payloads, including functional gene editors and a range of other enzymes, directly to the cytosol of targeted cells.
The company also announced the appointment of Dr. Edwin Moses as Chairman of the Board of Directors. Currently Chairman of Achilles Therapeutics plc, LabGenius Ltd and Avantium NV, Dr. Moses has a track record building and scaling innovative biotech platform companies, achieving multiple exits and raising over €700 million in equity and debt financing to date. Previously, he was CEO of Ablynx NV until its agreed takeover by Sanofi for $4.8 billion in 2018, and CEO of Oxford Asymmetry International plc prior to its sale to Evotec for £316 million. Dr. Moses led both companies’ successful IPOs on the London Stock Exchange, EuroNext and NASDAQ. His appointment as Chairman of NanoSyrinx’s Board of Directors will help support the executive team in maximising value from the Company’s nanosyringe platform, through a combination of in-house pipeline development and strategic commercial partnerships.
FinSMEs
10/09/2024